Mashkilleĭson A L, Golousenko I Iu
Vestn Dermatol Venerol. 1989(12):51-2.
The results of clinical trials of ditrastic, an agent manufactured by Orion, Finland, are analyzed. The drug contains 1.5 or 3% of ditranol. Of the 59 patients treated with this drug complete resolution of clinical eruptions was achieved in 43, the condition of 10 patients considerably improved, a partial effect was observed in 4, and no effect in 2 patients. Therefore ditrastic has proved to be a highly effective agent for the treatment of psoriasis, convenient for outpatient therapy.
对芬兰奥立安公司生产的一种药物ditrastic的临床试验结果进行了分析。该药物含有1.5%或3%的地蒽酚。在接受该药物治疗的59名患者中，43名患者的临床皮疹完全消退，10名患者的病情有显著改善，4名患者有部分疗效，2名患者无疗效。因此，ditrastic已被证明是一种治疗银屑病的高效药物，便于门诊治疗。
